MedTrace Logo

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

NCT06205628 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-22

No results posted yet for this study

Summary

This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.

Conditions

Interventions

DRUG

ADX-850

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Sponsors & Collaborators

  • ADARx Australia Pty Ltd

    collaborator UNKNOWN

  • ADARx Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Aditya Patel, MD · ADARx Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-21
Primary Completion
2026-07-31
Completion
2026-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06205628 on ClinicalTrials.gov